CMS finalizes Medicare coverage policy for Alzheimer’s drug

The Centers for Medicare & Medicaid Services yesterday finalized a decision to cover only for Medicare beneficiaries enrolled in qualifying clinical trials monoclonal antibodies that target amyloid to treat Alzheimer’s disease when approved by the Food and Drug Administration. The FDA last year approved the first such Alzheimer’s treatment, Biogen’s Aduhelm (aducanumab), using its accelerated approval pathway.
Related News Articles
Headline
The AHA April 30 released a report highlighting how hospitals and health systems continue to experience significant financial headwinds that can challenge…
Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…
News
The Centers for Medicare & Medicaid Services April 7 released finalized payment rates for calendar year 2026 Medicare Advantage and Part D plans. Payments…
Headline
The AHA today urged the Medicare Payment Advisory Commission to take specific actions on physician fee schedule payments following recommendations the…
Headline
The Centers for Medicare & Medicaid Services April 4 finalized changes to the Medicare Advantage and prescription drug programs for contract year 2026. The…
Chairperson's File
Rural hospitals and health systems face big challenges, but together — with a unified voice — we can work to ensure people living in rural communities get the…